Insmed Stock Earnings Reports

Insmed reported a strong start to 2026 driven by the BRINSUPRI launch and continued ARIKAYCE growth. BRINSUPRI delivered 44% sequential growth in Q1, strong payer access (~90% approval via specialty pharmacies), high patient enrollment in the inLighten support program (>80%), refill cadence near 30 days and continuation rates slightly above industry oral-medicine benchmarks. Prescriber breadth reached >5,000 cumulative writers (~25% of U.S. pulmonologists) with meaningful opportunity to deepen prescribing. Management reiterated full-year revenue guidance for BRINSUPRI of at least $1 billion. ARIKAYCE showed positive Phase IIIb ENCORE results (improved respiratory symptom scores and higher, durable culture conversion versus control); Insmed plans to submit ENCORE to U.S. and Japanese regulators in H2 2026 and says a broader label could expand the addressable ARIKAYCE population from ~30,000 to >200,000 patients, creating substantial upside. TPIP progress: first site opened for the Phase III PAH (PALM PAH) study, PALM-ILD enrolling across multiple countries, PPF/IPF Phase III designs nearing finalization, and OLE data (PAH) expected in Q3 2026; some OLE patients titrated to higher doses (up to 1,280 mcg). Financial position is solid with ~$1.2 billion cash and management expects sustainable cash-flow positivity in 2027 without needing additional capital if BD spend is limited. Notable risks/considerations: potential international launch complications tied to MFN pricing policy leading to a cautious approach outside the U.S.; future payer contracting/policy changes remain a variable (but approvals so far have been strong); and discontinuation dynamics are being monitored (management reports continuation rates above oral-medicine benchmarks).